Shares in Gemphire Therapeutics more than doubled after its lead drug gemcabene aced a midstage trial in patients with high triglycerides—setting up a phase 3 program.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,